Baxter International (BAX) reported that a European committee endorsed a new use for the drug Kiovig as a treatment for Multifocal motor neuropathy, a rare autoimmune disorder marked by progressive weakness in the limbs. With adoption by the European Commission Baxter will receive marketing authorization for KIOVIG MMN indication in all European Union Member States. Baxter International, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions.